Hormone Replacement Therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain by Chilet Rosell, Elisa et al.
CORRESPONDENCE Open Access
Hormone Replacement Therapy advertising:
sense and nonsense on the web pages of the
best-selling pharmaceuticals in Spain
Elisa Chilet-Rosell1,2*, Marta Martín Llaguno3, María Teresa Ruiz Cantero1,2, Pablo Alonso-Coello2,4
Abstract
Background: The balance of the benefits and risks of long term use of hormone replacement therapy (HRT) have
been a matter of debate for decades. In Europe, HRT requires medical prescription and its advertising is only
permitted when aimed at health professionals (direct to consumer advertising is allowed in some non European
countries). The objective of this study is to analyse the appropriateness and quality of Internet advertising about
HRT in Spain.
Methods: A search was carried out on the Internet (January 2009) using the eight best-selling HRT drugs in Spain.
The brand name of each drug was entered into Google’s search engine. The web sites appearing on the first page
of results and the corresponding companies were analysed using the European Code of Good Practice as the
reference point.
Results: Five corporate web pages: none of them included bibliographic references or measures to ensure that the
advertising was only accessible by health professionals. Regarding non-corporate web pages (n = 27): 41% did not
include the company name or address, 44% made no distinction between patient and health professional
information, 7% contained bibliographic references, 26% provided unspecific information for the use of HRT for
osteoporosis and 19% included menstrual cycle regulation or boosting feminity as an indication. Two online
pharmacies sold HRT drugs which could be bought online in Spain, did not include the name or contact details of
the registered company, nor did they stipulate the need for a medical prescription or differentiate between patient
and health professional information.
Conclusions: Even though pharmaceutical companies have committed themselves to compliance with codes of
good practice, deficiencies were observed regarding the identification, information and promotion of HRT
medications on their web pages. Unaffected by legislation, non-corporate web pages are an ideal place for indirect
HRT advertising, but they often contain misleading information. HRT can be bought online from Spain, without a
medical consultation or prescription constituting a serious issue for public health. In our information society, it is
the right and obligation of public health bodies to ensure that such information is not misleading.
Background
The balance between the benefits and risks of long term
use of hormone replacement therapy (HRT) has been a
matter of debate for decades. As early as 1939 the
review published by Nancy Krieger in 2005 on the his-
tory and epidemiology of hormone replacement therapy
(HRT) highlighted a potential association between HRT
and breast cancer [1]. It was not until the 70s that the
concern about endometrial cancer started [1]. Since the
publication of the Women’s Health Initiative (WHI) in
2002, detailing the higher incidence of cancer and cardi-
ovascular disorders in women on HRT, the benefits of
its long term use have been strongly questioned [2].
New clinical trials have confirmed these findings, con-
cluding that the risk-benefit profile for the prevention of
chronic conditions is generally unfavourable [3,4]. HRT
is no longer recommended routinely as a preventative
measure or as a first line treatment in the case of
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osteoporosis, nor for the prevention of chronic condi-
tions [5] (only some institutions still challenge this line
of though) [6]. Likewise, it is no longer indicated for
asymptomatic menopausal women [5,7]. Consequently,
there has been a steep drop in sales, documented mainly
in Anglo-Saxon countries [1].
Since 2004, the Spanish Agency for Medicine and
Health Care Products, in consonance with the regulatory
agencies in other countries, leading health care institu-
tions and most scientific societies, has considered HRT
to be potentially indicated only in the treatment of
severe climacteric symptoms with a negative effect on
quality of life. In this case, they concur that the mini-
mum effective dose should be used for the shortest pos-
sible duration [7,8].
HRT is classified as a prescription-only drug in Eur-
ope. That is, a medical prescription is required, and
therefore advertising is only permitted where it is aimed
at professionals authorised to prescribe, and not at the
general public [9]. Nevertheless in some non European
countries HRT direct to consumer advertising is
allowed. Furthermore, online sales are illegal in the Eur-
opean Union (EU). Despite this fact, online sales of
drugs in Europe have risen steeply since the 1990s,
becoming not only a risk to public health but also a sig-
nificant source of legal conflict between countries [10].
The EU has indicted the need to review the rigour,
integrity and consistency of health information pub-
lished on the Internet [11]. Spain adheres to the recom-
mendations given in the European Code of Good
Practice in the Promotion of Medicines adopted by the
European Federation of Pharmaceutical Industries and
Associations (EFPIA) [12]. This Federation requires each
affiliated national association to constitute a Committee
in order to ensure that companies fulfil the precepts of
the Code, and to undertake disciplinary proceedings
when appropriate. Specifically, Farmaindustria’s Code of
Practice Surveillance Unit in Spain supervises the Asso-
ciation’s code and advises members [13]. Meanwhile, in
Spain, it is the responsibility of the Jury of the Associa-
tion for Self-Regulation of Commercial Communications
to settle disputes and resolve disciplinary proceedings
concerning the code.
The aim of the European Code of Good Practice in
the Promotion of Medicines is to ensure that all phar-
maceutical promotion methods, including the Internet,
comply with current legislation [13]. Other objectives
include ensuring that the ethical principles of profes-
sionalism and responsibility are upheld, that access to
information aimed at professionals is restricted to the
target audience and that the identity of the advertiser is
clearly stated in the case of sponsored activities or for-
mats. Furthermore, it supports the obligatory inclusion
of information, comprising the Summary of Product
Characteristics and scientific information based on valid
data with scrupulous respect for truth and impartiality,
all within the framework of a balanced, clear explana-
tion. The need to avoid ambiguity is stressed, as is the
need to base advertising claims on firm scientific evi-
dence and medical opinion, which the reader is able to
check up on (i.e. compliance with the code requiring
inclusion of bibliographic references). Likewise, exag-
geration or omission of data is forbidden [13].
In order to analyse the phenomena of HRT internet
advertising in Spain, this research has three main
objectives:
1. To estimate compliance with these regulations on
the corporate web pages of the best-selling HRT drugs
in Spain, in order to identify the degree of commitment
of the corresponding pharmaceutical companies.
2. To analyse references to the same drugs on non-
corporate web pages, establishing the name and address
of the registered company and possible sponsors, in
order to identify potential connections or ties with phar-
maceutical companies.
3. To evaluate and quantify whether these prescrip-
tion-only drugs are being sold on the Internet to the
general public via online pharmacies based in Spain or
abroad.
Methods
In order to obtain the list of the best-selling and most
frequently prescribed HRT brands in Spain, the Spanish
Ministry of Health and Consumer Affairs General Direc-
torate was consulted. These top eight products were
Absorlent Plus, Activelle, Duofemme, Estalis, Estracomb,
Merigest, Perifem and Progyluton.
Using the drugs’ commercial brands, a search was car-
ried out in January 2009, simulating the kind of search
strategy that a typical internet user interested in locating
information about these drugs would employ, using the
Google search engine (the most popular search engine
amongst internet users) [14]. All the web sites appearing
on the first results page for each of the drugs were
selected. In addition, when the first results page for each
drug did not include the corporate web page, that is, the
web site of the company marketing the drug in Spain, a
further search was made in order to locate it, and the
information about the drug analysed.
The corporate web sites were analysed for compliance
with the following European Code’s recommendations:
1. Restriction of the information to a specialised public
(implemented through obligatory identification on behalf
of the user in order to access the information). Specifi-
cally, the obligation to register - supplying the profes-
sional body membership number - in order to access
information aimed at health care professionals, was
monitored.
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2. Obligatory inclusion of the drug’s Summary of Pro-
duct Characteristics.
3. Conformity of the indications with the Patient
Information Leaflet (for this, the Patient Information
Leaflet approved by the Spanish Agency of Medicine
and Health Care Products for each drug was consulted).
4. Inclusion of the registered company name and
address.
5. Inclusion of complete bibliographic references,
including references to the original source.
Additionally, compliance with these same recommen-
dations on non-corporate web pages referring to the
same drugs was studied. If this information was not
already explicitly stated on the page, the registered com-
pany name and address, and possible sponsorship, was
identified using the website http://www.whois.net (this
website offers domain-based research services).
The following information was also collected on non-
corporate web pages:
- Whether the page offered links to sites selling
medicines.
- Erroneous or inadequate information concerning
drug indications.
The legal status of the online pharmacies was deter-
mined on the basis of the inclusion of the registered
company name and address. In these cases, the availabil-
ity of the drug’s Summary of Product Characteristics,
the stipulation of the need for a prescription and the
presence of restrictions on access to the information, as
well as the possibility of purchasing prescription-only
medication from Spain was studied.
Results
Out of a total of 70 web pages (see Additional File 1),
corresponding to the eight HRT drugs studied were
retrieved from Google. After the exclusion of the
repeated web pages, 34 were analysed (Figure 1). Of
these 34 web pages, five were corporate web sites
(Table 1), 27 were non-corporate (23 web pages provid-
ing medical information and four forums) (Table 2), and
two were online pharmacies (Table 3).
Table 1 includes the characteristics of the web pages
provided by pharmaceutical companies marketing the
HRT drugs analysed. Inclusion of the registered com-
pany name and address was the only issue fulfilled by
them all. The application of measures to ensure that
medication advertising was restricted to health profes-
sionals was apparent only in the case of one company
(Organon Española SA.). Three other web pages
required the user to register, but did not require a pro-
fessional body membership number, whilst Bayer
applied no control over access to information. Only two
web pages complied with the precept of including the
Summary of Product Characteristics, and three others
presented the medication indications as given in the
Spanish Drug Formulary. None of them included biblio-
graphic references or cross-references to the original
studies.
Table 2 presents the characteristics of non-corporate
web pages offering medical information or forums
where some of the medications studied were mentioned.
Of the 27 non-corporate web pages, 11 (41%) provided
no information concerning the registered company
name and address. As for the obligation to include the
Summary of Product Characteristics, 22 (81.5%) did not
comply and a further five (18.5%) did not include the
indications as provided in their corresponding Patient
Information Leaflet.
Several inappropriate HRT therapeutic indications
were recorded for 11 web pages: seven (26%) indicated
HRT treatment for osteoporosis without mentioning a
note of caution or the restrictions imposed by the Min-
istry for Health and Consumer Affairs due to the unfa-
vourable risk-benefit profile [6,7]. Five (19%) indicated
HRT as a means of regulating the menstrual cycle (four
of these pages were forums), and one (4%) forum com-
mented on the use of two HRT medications for “boost-
ing femininity”.
Two web pages (7%) providing medical information
fulfilled the requirement of including bibliographic
references and references to the original source. Results
for providing different levels of information to patients
and health professionals were mixed: 16 web pages
made no distinction, five pages made no distinction but
did insist on the need to consult a professional, five dif-
ferentiated between patients and health professionals
but did not restrict access to the information, and only
one required the user to register in order to access the
information, but did not require the user to prove their
health professional status. Among the non-corporate
web pages providing medical information, three
included links to the sale of medications, although these
did not include HRT drugs.
None of the two online pharmacies (http://www.gold-
pharma.com and http://www.rx-med.net) included had
its base in Spain, although one was based in the Eur-
opean Union, specifically, the United Kingdom. None of
them complied with the requirements analysed (inclu-
sion of registered company name and address, Summary
of Product Characteristics, prescription only status and
differentiation between information aimed at the patient
and that aimed at the health professional). In the case of
these online pharmacies, medications could be pur-
chased from Spain. Regarding legal status, Goldpharma
(registered in the Seychelles, according to http://www.
whois.net) placed the onus probandi (burden of proof)
on the user to check current legislation for each country
and accepted no responsibility. Likewise, Rx-med
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Figure 1 Selection of Web of best selling HRT drugs in Spain to be analysed.
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(registered in the UK, according to http://www.whois.
net) sells worldwide, but accepted no responsibility for
compliance with legislation in other countries.
Discussion
Despite important efforts by the European Union to reg-
ulate and control medicines, our study shows that the
European Code of Good Practice for the Promotion of
Medicines has not had the desired effect on the quality
of the information available on the best selling pharma-
ceuticals in Spain.
The corporate web pages of pharmaceutical companies
owning HRT drugs do not comply with all the precepts
laid down in this Code. On the other hand, forums and
non-corporate web pages are promoting HRT irrespec-
tive of EU regulations. These websites contain misleading
or erroneous information about the potential therapeutic
uses of HRT, the information they provide is rarely based
on scientific evidence, and they sometimes publicise
online pharmacies. Similarly, the study confirmed a well-
known fact that, despite EU prohibitions, it is still
possible and easy to buy HRT medications from online
pharmacies from anywhere in the world.
For women seeking information about the benefits and
risks associated with HRT, there is a wealth of informa-
tion available, but this is frequently contradictory. Much
of this information is found in the media. For example,
the first item retrieved by our search on the web page of
the Spanish Agency for Medicines was the 2002 warning
[15], where the use of HRT in the prevention of osteo-
porosis continued to be recommended. However, the
2004 [16] warning, restricting its use, did not appear dur-
ing this search, whilst the 2008 warning appeared in sec-
ond place, despite being the most current [17].
HRT has for decades been the source of a conflictive
debate between pharmaceutical companies, epidemiolo-
gists, regulatory agencies and feminist groups. If a
woman searches for HRT information online, the infor-
mation she will find will be confusing, incomplete and
frequently erroneous. In fact, women can even buy HRT
online, without a prescription or medical advice and
monitoring. This fact is particularly alarming since HRT
drugs are powerful pharmacological agents shown to be
thrombogenic and carcinogenic in the long term [2-4].
Significant inappropriate HRT indications were
observed in the advertising published on the web pages
analysed, for example indicating the use of HRT to pre-
vent osteoporosis whilst failing to mention the restric-
tions imposed on this particular use [7,8]. Of greater
concern is the fact that these sites promote other thera-
peutic uses for which the medication has not been
approved, such as “boosting femininity” or regulating
the menstrual cycle. These indications could involve a
long-term use, which might constitute a significant
health risk to the consumer, according to the evidence
currently available [2-4].
Controlling the promotion and sale of medicines
through indirect online marketing presents a challenge
to European regulatory bodies. Unaffected by any regu-
lations in this respect, forums, chat rooms and non-cor-
porate web pages all constitute an ideal place to
promote medications indirectly, and to broaden the
scope of drugs’ therapeutic applications. Thus, faced
with the impossibility of generating direct demand for
prescription-only drugs in Europe, pharmaceutical mar-
keting may exploit these “disease mongering” strategies
for menopausal and postmenopausal women [19-21].
Osteoporosis has been classified as a disease only in so
Table 1 Compliance with Farmaindustria’s “Code of Good Practice for the Promotion and Use of Medicines” on the
web pages of pharmaceutical companies marketing the best-selling HRT drugs in Spain.
Web Site Registration Required Registered
Company Name
and Address Given
Summary of
Product
Characteristics
Therapeutic
Indications
Bibliographic
References
http://www.esteve.es Must register, but professional
body membership number
not required
Yes Yes Yes No references
http://www.isdin.es Must register, but professional
body membership number
not required
Yes Yes Yes No references
http://www.novartis.es Must register, but professional
body membership number
not required
Yes Information about
HRT products does
not appear
Information about
HRT products does
not appear
Information about
HRT products does
not appear
http://www.organon.es Must register and provide
professional body
membership number
Yes Information about
Perifem does not
appear
Information about
Perifem does not
appear
Information about
Perifem does not
appear
http://www.
bayerscheringpharma.es
Registration not required Yes No (patient
information is given)
Yes No references
(Web pages consulted January 2009)
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Table 2 Compliance with Farmaindustria’s “Code of Good Practice for the Promotion and Use of Medicines” on non-
corporate web pages (Information and Forums) promoting the best-selling HRT drugs in Spain.
Portal/HRT drug Registered
name/Co
address
Data
Sheet
Indications Erroneous
Indications
References Differentiated patient
physician information
http://www.dkvseguros.com (*): Absorlent Plus Yes No No No No. Must consult a
doctor
http://www.nomenclator.org (*): Absorlent Plus,
Activelle, Duofemme, Estalis, Merigest, Perifem
No No No No No
http://www.vademecum.es (*): Absorlent Plus,
Activelle, Duofemme, Estalis, Estracomb, Merigest,
Perifem, Progyluton
Yes No Yes Osteoporosis
unspecific
prevention
No Yes, but does not require
professional body
membership number
http://www.epgonline.org (*): Absorlent Plus Yes No Yes Osteoporosis
unspecific
prevention
No No
http://www.farmacopedia.com (*): Absorlent Plus,
Activelle
No No No No No. Must consult a
professional
http://www.diagnosticomedico.es (*): Absorlent
Plus, Activelle, Estalis Merigest, Perifem
No No No No No
http://www.prospectos.net (*): Activelle No No Yes Yes Yes, but does not require
professional body
membership number
http://www.agemed.es (*): Activelle, Duofemme,
Merigest, Perifem, Progyluton
Yes Yes Yes No Yes, but does not require
professional body
membership number
http://www.laboratoriosilesia.com (*): Activelle Yes No Yes No No
http://www.novasalud.cl (*): Activelle Yes No Yes Yes Yes, but does not require
professional body
membership number
http://www.solucionestraumatologicas.com (*):
Activelle
Yes No Yes No No
http://www.concursossanitarios.com/(*):
Duofemme, Merigest, Perifem
Yes No No No No
http://www.famguerra.com (*): Estalis, Estracomb No Yes Yes Osteoporosis
unspecific
prevention
No No
http://www.medbroadcast.com (*): Estalis,
Estracomb
Yes No Yes No No. Must consult a
professional
http://www.novartis.ca (*): Estalis, Estracomb Yes Yes Yes No Yes, but does not require
professional body
membership number
http://www.facmed.unam.mx (*): Estalis,
Estracomb
Yes No Yes Osteoporosis
unspecific
prevention
No No
http://www.saludzac.gob.mx (*): Estalis Yes No Yes Osteoporosis
unspecific
prevention
No No
http://www.rxmed.com (*): Estracomb No Yes Yes Osteoporosis
unspecific
prevention
No No. Must consult a
professional
http://www.pdamecum.com (*): Estracomb Yes Yes Yes No Yes, but does not require
professional body
membership number
http://www.healthyontario.com (*): Estracomb Yes No Yes No No
http://chealth.canoe.ca/(*): Perifem Yes No Yes No No. Must consult a
professional
http://www.hipocrates.com (*): Progyluton No No Yes No No
http://www.cmp-sanmartin.org (*): Duofemme,
Perifem, Progyluton
Yes No Yes Menstrual cycle
Regulation/
osteoporosis
Prevention
No No
http://www.enfemenino.com (**): Perifem,
Progyluton
No. No Yes Menstrual cycle
Regulation
No No
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far as it increases the risk of suffering a fracture [19,20],
whilst the menopause, which is a normal part of the life
cycle, is often advertised as pathological[21]. In both
cases, HRT has been recommended and prescribed,
leading to the perception of real diseases in the popula-
tion [22].
At present, no specific body exists in Spain with the
express remit of monitoring online sales of unauthorised
medications. Due to the protection offered by the supra-
national structure of the Internet, countries possessing
strict pharmaceutical controls have recently been over-
whelmed with medications acquired in other countries
with more permissive health legislations, and to date
have been unable to prevent the phenomenon [9]. HRT
drugs are sold in Spain on commercial web sites which
exempt themselves from any responsibility regarding the
purchase. Their registered headquarters are located in
countries where such sales are either not legislated for,
as is the case of sales from the Seychelles identified in
this study, or illegal, as is the case of sales from the UK.
Such uncontrolled sale of HRT drugs without a medical
consultation or prescription constitutes a serious threat
to public health, in this case more precisely to the
women’s population.
Since the pharmaceutical companies have a vested
interest in the quality and ethical and legal status of the
information provided about their products, it was the
industry itself which agreed to implement self-regulation
regarding promotion. Thus, the pharmaceutical
companies committed themselves to compliance with
codes of good practices for the promotion of medicines
[13,14]. However, it may be that this strategic decision
is actually one of the reasons behind the deficiencies
observed regarding the identification, information and
promotion of HRT medications on the Internet. Farm-
aindustria’s Code of Practice Surveillance Unit has a
great deal of work ahead of it if the corporate web
pages are to be compelled to respect the codes of con-
duct. As this study has shown, in general, the companies
do not require the user to register as a health care pro-
fessional in order to access the information provided on
the page, nor do the pages facilitate bibliographic refer-
ences which provide objective support for the informa-
tion. Furthermore, these companies do not include the
necessary information concerning the pharmaceutical
characteristics of their HRT drugs on their web pages.
Health information sites have proliferated, and in
Spain there are now over 6,000 disease-related virtual
forums [16]. These websites represent an important
source of health information. The infringement of ethi-
cal requirements on these non-corporate web sites con-
stitutes a danger to Public Health, given that 80% of
patients now use the Internet to find information about
their disorders [17]. Therefore, independently of official
bodies, pharmaceutical companies should take the initia-
tive in monitoring the suitability of information pro-
vided about their drugs on forum sites, chat rooms and
non-corporate web pages. Furthermore, they ought to
Table 3 Characteristics of Pharmacies on line promoting the best-selling HRT drugs in Spain.
Portal and HRT drug Registered
name/Co.
address
Address of
company http://
www.whois.net
Data
Sheet
Requirement Differentiated
patient/
professional
information
Sales in Spain
http://www.goldpharma.
com: Absorlent plus,
Duofemme, Estalis
Estracomb, Merigest
Perifem
No Seychelles Islands No No No Burden of proof on the user to check
current legislation for each country and
accepted no responsibility
http://www.rx-med.net:
Duofemme, Merigest
Perifem
No United Kingdom No No No Sells worldwide, but accepted no
responsibility for compliance with
legislation in other countries
(Web pages visited January 2009).
Table 2: Compliance with Farmaindustria’s “Code of Good Practice for the Promotion and Use of Medicines” on non-
corporate web pages (Information and Forums) promoting the best-selling HRT drugs in Spain. (Continued)
http://www.carlaantonelli.com (**): Progyluton No No Yes Boosts femininity/
Menstrual cycle
Regulation
No No
http://www.portalesmedicos.com (**): Progyluton No No Yes Menstrual cycle
Regulation
No No
http://es.answers.yahoo.com (**): Progyluton No No Yes Menstrual cycle
Regulation
No No
(Web pages visited January 2009)
Type of web page: (*) Medical information, (**) Forum. Co.: Company
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display the same concern over the quantity of informa-
tion available on the Internet about their products as
they do over unfair publicity from their peers [18].
The limitations of our study are related to the
dynamic nature of the Internet, where content may vary
each time a page is updated. Furthermore, it is possible
that a search carried out at any time other than January
2009, could produce other web sites on the first results
page. In addition, the selection of web sites did not
comprise all the information and advertising available
for each HRT drug analysed, as only the web sites
appearing on the first results page were selected for ana-
lysis. Nevertheless, evidence suggests that users rarely
look beyond the first results page [22].
Beyond the interests of pharmaceutical companies for
the quality advertising of their products, and particularly
in the promotion and sale of these products on the
Internet, it is, as Muir Gray states, the right and obliga-
tion of public health bodies in an information society to
ensure that such information is not misleading in terms
of health, disease and pharmaceutical therapies. To date,
the health authorities have yet to make a serious move
in this direction [23].
Conclusions
Controlling the promotion and sale of medicines
through indirect online marketing represents a challenge
to European regulatory bodies. Even though pharmaceu-
tical companies have committed themselves to compli-
ance with codes of good practice for the promotion of
medicines, deficiencies were observed regarding the
identification, information and promotion of HRT medi-
cations on their web pages. Unaffected by legislation,
non-corporate web pages are an ideal place for indirect
HRT advertising often containing misleading informa-
tion. HRT can be bought online from Spain, without a
medical consultation or prescription constituting a ser-
ious public health issue.
Additional file 1: Annex 1. List of the web sites retrieved in the search
of the best selling HRT pharmaceuticals in Spain.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2458-10-
134-S1.DOC ]
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